Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.
Daniela Rezende JunqueiraBrian H RowePublished in: British journal of clinical pharmacology (2020)
The RCTs investigating HQ or chloroquine during the early stages of the COVID-19 pandemic included heterogeneous and insufficient approaches to measure efficacy/effectiveness and safety relevant to patients and clinical practice. These findings provide insights to inform clinical and regulatory decisions that can be drawn about the efficacy/effectiveness and safety of these agents in patients with COVID-19. Trialists need to adapt quickly to the research progress on COVID-19, ensuring that core outcome measures are assessed in ongoing RCTs.
Keyphrases
- end stage renal disease
- clinical practice
- randomized controlled trial
- sars cov
- coronavirus disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- prognostic factors
- systematic review
- metabolic syndrome
- type diabetes
- clinical trial
- patient reported outcomes
- plasmodium falciparum
- skeletal muscle
- patient reported